Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 1;18(10):1310-1320.
doi: 10.2215/CJN.0000000000000229. Epub 2023 Jul 27.

Stakeholder Perspectives on Factors Related to Deprescribing Potentially Inappropriate Medications in Older Adults Receiving Dialysis

Affiliations

Stakeholder Perspectives on Factors Related to Deprescribing Potentially Inappropriate Medications in Older Adults Receiving Dialysis

Rasheeda K Hall et al. Clin J Am Soc Nephrol. .

Abstract

Background: Potentially inappropriate medications, or medications that generally carry more risk of harm than benefit in older adults, are commonly prescribed to older adults receiving dialysis. Deprescribing, a systematic approach to reducing or stopping a medication, is a potential solution to limit potentially inappropriate medications use. Our objective was to identify clinicians and patient perspectives on factors related to deprescribing to inform design of a deprescribing program for dialysis clinics.

Methods: We conducted rapid qualitative analysis of semistructured interviews and focus groups with clinicians (dialysis clinicians, primary care providers, and pharmacists) and patients (adults receiving hemodialysis aged 65 years or older and those aged 55-64 years who were prefrail or frail) from March 2019 to December 2020.

Results: We interviewed 76 participants (53 clinicians [eight focus groups and 11 interviews] and 23 patients). Among clinicians, 24 worked in dialysis clinics, 18 worked in primary care, and 11 were pharmacists. Among patients, 13 (56%) were aged 65 years or older, 14 (61%) were Black race, and 16 (70%) reported taking at least one potentially inappropriate medication. We identified four themes (and corresponding subthemes) of contextual factors related to deprescribing potentially inappropriate medications: ( 1 ) system-level barriers to deprescribing (limited electronic medical record interoperability, time constraints and competing priorities), ( 2 ) undefined comanagement among clinicians (unclear role delineation, clinician caution about prescriber boundaries), ( 3 ) limited knowledge about potentially inappropriate medications (knowledge limitations among clinicians and patients), and ( 4 ) patients prioritize symptom control over potential harm (clinicians expect resistance to deprescribing, patient weigh risks and benefits).

Conclusions: Challenges to integration of deprescribing into dialysis clinics included siloed health systems, time constraints, comanagement behaviors, and clinician and patient knowledge and attitudes toward deprescribing.

PubMed Disclaimer

Conflict of interest statement

C. Colón-Emeric reports consultancy for Amgen and Novartis, research funding from UCB, co-inventor 2 use patents for bisphonate indication in cardiovascular diseases, and advisory or leadership roles for Amgen and Novartis. L.J. Fish reports advisory or leadership role as Board President of Be the Village. R.K. Hall reports consultancy for Bayer, Chinook, Goldfinch, Inside Edge, Otsuka, Reata Pharmaceuticals, Third Bridge, Travere Pharmaceuticals, and United Health Group; ownership interest in Pfizer and Vertez; advisory or leadership role for the CJASN Editorial Board, Journal of American Geriatrics Society Editorial Board, Kidney360, and Pediatric Nephrology; speakers bureau for Inside Edge and Otsuka; and other interests or relationships as owner of Internal Shifts Coaching LLC. A. Lucas reports an advisory or leadership role for American Kidney Fund Medical Advisory Committee. W. St. Peter reports the consultancy for CSL-Vifor Pharma, GSK, and Total Renal Care, Inc.; honoraria from American Nephrology Nursing Association, Integritas Group, Letters and Sciences, and OptumLabs; advisory or leadership role as Scientific Advisory Board Member for National Kidney Foundation; and other interests or relationships with Centers for Medicare and Medicaid Services Technical Expert Panel on Development of a Quality Measure Assessing Delay in Progression of Chronic Kidney Disease (CKD), NKF and ASN Task Force on eGFR and Race, and Technical Expert Panel for Quality Insights Kidney Care Pilot project. J. St. Clair Russell reports consultancy for AdheaRx and Renalytix. J. Rutledge reports research funding from NephroNet, Inc. and Vifor Pharma, Inc. The remaining author has nothing to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
The deprescribing process. A schematic of the deprescribing process provided during clinician focus groups and interviews. Adapted from ref. , with permission. PIMs, potentially inappropriate medications.
Figure 2
Figure 2
Patient responses from Patients' Attitudes towards Deprescribing questionnaire. This is a bar graph of participant responses to items included in the revised Patients' Attitudes towards Deprescribing questionnaire. Participants could choose one or none of “Strongly disagree” (1), “Disagree” (2), “Unsure” (3), “Agree” (4), “Strongly agree” (5). Shown here are combined responses for agree/strongly agree and disagree/strongly disagree. N=23 for all items.

Comment in

References

    1. Kondo N Nakamura F Yamazaki S, et al. . Prescription of potentially inappropriate medications to elderly hemodialysis patients: prevalence and predictors. Nephrol Dial Transplant. 2015;30(3):498–505. doi:10.1093/ndt/gfu070 - DOI - PubMed
    1. Parker K, Aasebo W, Stavem K. Potentially inappropriate medications in elderly haemodialysis patients using the STOPP criteria. Drugs Real World Outcomes. 2016;3(3):359–363. doi:10.1007/s40801-016-0088-z - DOI - PMC - PubMed
    1. Daubresse M, Alexander GC, Crews DC, Segev DL, McAdams-DeMarco MA. Trends in opioid prescribing among hemodialysis patients, 2007-2014. Am J Nephrol. 2019;49(1):20–31. doi:10.1159/000495353 - DOI - PMC - PubMed
    1. Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol. 2018;29(7):1970–1978. doi:10.1681/ASN.2018010096 - DOI - PMC - PubMed
    1. Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Psychoactive medications and adverse outcomes among older adults receiving hemodialysis. J Am Geriatr Soc. 2019;67(3):449–454. doi:10.1111/jgs.15740 - DOI - PubMed

Publication types

LinkOut - more resources